Novo Nordisk is reporting shortages of Ozempic, Wegovy, Saxenda and, recently, Eli Lilly has reported shortages of Mounjaro, a Type 2 diabetes drug that might be approved for weight loss if clinical trials find success.
Eli Lilly's 7.5, 12.5 and 15 milligram solutions of Mounjaro are in short supply, and the drugmaker predicts supply levels to normalize by the end of July, the FDA said in a July 25 post. The 10 milligram solution is also on back order, and that shortage is expected to end in September.
The company listed the reason for the shortage as "demand increase."